- Home
- CCIR vs RLAY Comparison
CCIR vs RLAY Comparison
Compare CCIR & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIR
- RLAY
- Stock Information
- Founded
- CCIR 2021
- RLAY 2015
- Country
- CCIR United States
- RLAY United States
- Employees
- CCIR N/A
- RLAY N/A
- Industry
- CCIR
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCIR
- RLAY Health Care
- Exchange
- CCIR NYSE
- RLAY Nasdaq
- Market Cap
- CCIR 409.5M
- RLAY 490.3M
- IPO Year
- CCIR 2024
- RLAY 2020
- Fundamental
- Price
- CCIR $11.48
- RLAY $3.24
- Analyst Decision
- CCIR
- RLAY Strong Buy
- Analyst Count
- CCIR 0
- RLAY 11
- Target Price
- CCIR N/A
- RLAY $18.40
- AVG Volume (30 Days)
- CCIR 264.2K
- RLAY 1.6M
- Earning Date
- CCIR 01-01-0001
- RLAY 05-05-2025
- Dividend Yield
- CCIR N/A
- RLAY N/A
- EPS Growth
- CCIR N/A
- RLAY N/A
- EPS
- CCIR 0.12
- RLAY N/A
- Revenue
- CCIR N/A
- RLAY $7,679,000.00
- Revenue This Year
- CCIR N/A
- RLAY $14.58
- Revenue Next Year
- CCIR N/A
- RLAY N/A
- P/E Ratio
- CCIR $93.09
- RLAY N/A
- Revenue Growth
- CCIR N/A
- RLAY N/A
- 52 Week Low
- CCIR $9.92
- RLAY $1.78
- 52 Week High
- CCIR $13.35
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- CCIR N/A
- RLAY 58.47
- Support Level
- CCIR N/A
- RLAY $2.75
- Resistance Level
- CCIR N/A
- RLAY $3.39
- Average True Range (ATR)
- CCIR 0.00
- RLAY 0.20
- MACD
- CCIR 0.00
- RLAY 0.04
- Stochastic Oscillator
- CCIR 0.00
- RLAY 76.56
About CCIR COHEN CIRCLE ACQUISITION CORP I
Cohen Circle Acquisition Corp I is a blank check company.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).